Navigation Links
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Date:5/25/2011

children ages 2 years and older.
  • ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
  • ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
  • ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

  • If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    Please see Prescribing Information and Medication Guide at www.ENBREL.com.

    ENBREL in the EU is approved for the following indications:

  • Rheumatoid arthritis: ENBREL in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.  ENBREL can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.  ENBREL is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  ENBREL, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
  • Polyarticular juvenile idiopathic arthritis: Treatment of active polyarticular juvenile idiopathic arthritis (JIA) in children and a
    '/>"/>

  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
    4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
    5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
    6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
    7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
    8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
    9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
    10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
    11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
    (Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
    (Date:7/24/2014)... , and MARSEILLE, France , July ... Exclusive global license from University of Tokyo enables development ... (NGS) gene panels, for blood cancers  Mutations ... indicate favorable prognosis for patients with bone marrow disorders ... for developing companion diagnostics to guide treatment with new ...
    Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
    ... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
    ... shows, investigational regimen resulted in 82 percent overall survival and 78 ... ... is presently being conducted in this ... patient population, LUGANO, Switzerland, June 9 In an ...
    Cached Medicine Technology:Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 2Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 3Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 4
    (Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
    (Date:7/25/2014)... As reported by Wood TV 8 in the article ... seen a nearly 500-person increase in heroin related overdose deaths ... between 1999 and 2002, the toll increased to 728 during ... states, drug users in Michigan have turned to heroin after ... the price of both substances, noting that an 80-milligram pill ...
    (Date:7/25/2014)... (PRWEB) July 25, 2014 Reproductive Science ... announce that Dr. Kerri Luzzo, Lead Physician at RSC ... for her professional accomplishments in fertility care and community ... At the 10th Annual PBN Awards ceremony held July ... 40 of the most highly regarded, emerging leaders in ...
    (Date:7/25/2014)... 25, 2014 As reported by People Magazine ... After Jersey Shore and Getting Sober (7/15), one of ... Shore, has spoken out to the public about his personal ... show, The Situation admits that moving on with his life ... drugs, and other drugs in 2012 and even spent some ...
    (Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational partnership ... come and make a difference in the Tampa Bay community. ... to provide the support needed to keep the science center ... the IMAX Dome Theatre from film to a state-of-the-art digital ... Theatre in the state of Florida, and it is one ...
    Breaking Medicine News(10 mins):Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4
    ... and ... Children,s Hospital Boston, BOSTON, April 8, 2008 Hess ... help support,children with medical needs through the Jimmy Fund and the ... every home run hit during a New,England Sports Network (NESN) televised ...
    ... Building Innovations, Products Help Protect and Preserve Buildings, ... DuPont (NYSE:,DD) and The Energy and Resources Institute ... the cause of green building design and,certification in ... Kalsi, president of DuPont India,and Dr. R. K. ...
    ... Distort State Funding, HARRISBURG, Pa., April 8, ... by more than $500 million in the past ... today expressed,continuing concern about misleading claims from nursing ... Pennsylvania,s nursing,home facilities., "Nursing home representatives seem ...
    ... PITTSBURGH, April 8, 2008 Precision Therapeutics ... it signed contracts with,National Preferred Provider Network ... NPPN, headquartered in Middletown, NY, is ... country representing more than seven million lives. ...
    ... at Events Nationwide Saturday, April 12, to Help ... 8, 2008 On Saturday, April 12, more than,600,000 ... Healthy,Kids(R) Day -- the nation,s largest health day for ... YMCA Healthy Kids Day encourages families,to "Put Play in ...
    ... Auctions off Flight Simulator Experience on eBay, ... one lucky guest in the captain,s seat in ... Cancer Society (ACS), United is auctioning off a,behind-the-scenes ... Flight Training Center in Denver, Colo., including two ...
    Cached Medicine News:Health News:Every Boston Red Sox Home Run Televised on NESN in 2008 to Help Children With Medical Needs 2Health News:Every Boston Red Sox Home Run Televised on NESN in 2008 to Help Children With Medical Needs 3Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 2Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 3Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 4Health News:Precision Therapeutics Adds 8 Million Covered Lives Under Contract 2Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 2Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 3Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 4Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 5Health News:Be in the Captain's Seat in the Fight Against Cancer 2Health News:Be in the Captain's Seat in the Fight Against Cancer 3
    The precise, fully reusable R-100 Pullback Device is an invaluable tool during plaque volumetric analysis....
    ... you perform exams from cardiac to angio. ... no compromises. An ideal 31 centimeters square, ... of cardiovascular and interventional imaging. With a ... variety of vascular and interventional procedures. The ...
    ... The RX daytona is a fully ... field in bench top analysers offering many ... standing systems. With reusable glass cuvettes, on ... and reagents, the random access analyser can ...
    Inquire...
    Medicine Products: